-
Annual meeting: director nominees elected, auditor ratified, say-on-pay approved
Directors Desai (28.4M for, 8.5M withheld), Garrett (29.2M for, 7.8M withheld), Moll (36.5M for, 0.5M withheld) elected.
-
PROCEPT BioRobotics Reports Q1 2026 Revenue of $83.1M, Up 20% YoY; Net Loss Widens to $31.6M
Total revenue $83.1M, +20% YoY; U.S. procedures 12,200, +30% YoY.
-
Appoints Daniel Puckett as new board member and Audit Committee member
Board expanded from 8 to 9 members; Puckett appointed effective March 5, 2026.
-
PROCEPT BioRobotics holds Investor Day; no specific data disclosed in 8-K exhibit excerpt
Investor Day held Feb 26, 2026 at NASDAQ HQ; presentation furnished as Exhibit 99.1.
-
PROCEPT BioRobotics Q4 rev $76.4M (+12% YoY), net loss $29.8M; FY26 guidance $390-410M
Q4 total revenue $76.4M (+12% YoY); U.S. procedures ~12,200 (+69% YoY).
-
PROCEPT Q3 revenue $83.3M (+43% YoY); issues FY2026 guidance $410M-$430M
Q3 total revenue $83.3M, up 43% YoY; U.S. handpiece/consumables $44.4M (+50% YoY).
-
PROCEPT BioRobotics modifies severance for non-CEO execs: severance doubled to 12 months, lump sum on change of control
Severance period for non-CEO execs increased from 6 to 12 months for termination without cause not tied to a change of control.
-
PROCEPT Q2 revenue $79.2M (+48% YoY); raises FY25 guidance; appoints new CEO
Q2 total revenue $79.2M, up 48% YoY; U.S. handpiece/consumables $43.1M (+58%).
-
PROCEPT BioRobotics appoints Larry Wood as CEO, pre-announces Q2 revenue of $79.2M (+48% YoY)
Larry L. Wood becomes President and CEO effective Sept 2, 2025; succeeds Reza Zadno who retires.
-
Procept BioRobotics stockholders elect directors, ratify auditor, approve say-on-pay
Directors elected: Little (31.8M votes for), Prescott (41.7M), Wood (39.8M); broker non-votes 4.35M.
-
Procept BioRobotics presents at AUA investor event; no financial details in filing excerpt
Company furnished presentation slides for AUA annual meeting on April 25, 2025.
-
PROCEPT BioRobotics Q1 revenue up 55% to $69.2M; raises FY2025 guidance to $323M
Total revenue $69.2M, +55% YoY; U.S. revenue $60.3M (+50%); international $8.9M (+104%).
-
PROCEPT BioRobotics Q4 revenue up 57% to $68.2M; guides FY2025 revenue ~$320M (+42%)
Q4 rev $68.2M (+57% YoY); US system rev $27.6M (+67%); handpiece rev $29.3M (+36%).
-
PROCEPT BioRobotics issues ~1.92M shares at $91/share, nets ~$163.8M in public offering
Company sold 1,923,076 shares at $91 per share; net proceeds to company were ~$163.8M after discounts and expenses.
-
PROCEPT BioRobotics Q3 revenue $58.4M (+66% YoY); raises 2024 revenue and EBITDA guidance
Q3 revenue $58.4M, up 66% YoY; U.S. handpiece+consumables $29.6M (+74%).
-
PROCEPT BioRobotics receives FDA 510(k) clearance for HYDROS Robotic System
HYDROS features FirstAssist AI for AI-powered treatment planning using real-world procedure data.
-
PROCEPT BioRobotics Q2 revenue $53.4M (+61% YoY); raises FY2024 revenue and EBITDA guidance
Total revenue $53.4M (+61% YoY); U.S. handpiece & consumables $27.3M (+101% YoY).
-
Director Krummel resigns; Thomas M. Prescott appointed new board member and chairperson
Dr. Thomas Krummel resigned from Board and Compensation Committee effective July 18, 2024; no disagreement with company.
-
Procept BioRobotics shareholders elect three directors, ratify auditor, approve executive compensation at annual meeting
Amy Dodrill, Taylor Harris, and Reza Zadno elected to board with majority vote.
-
PROCEPT BioRobotics furnishes investor presentation; no specific financial data disclosed
Company will present at investor conferences starting May 3, 2024, using slides furnished as Exhibit 99.1.
-
PROCEPT BioRobotics announces Q1 2024 earnings; press release not included in filing
The 8-K filing references a press release dated May 1, 2024 for Q1 2024 financial results.
-
Director Colby Wood resigns; Larry Wood appointed to board and audit committee
Colby Wood resigned as director and Audit Committee member effective April 18, 2024; no disagreement cited.
-
PROCEPT BioRobotics issues Q4 2023 earnings release; key metrics not disclosed in filing body
Press release furnished as Exhibit 99.1 contains full financial results; not included in extracted text.
-
PROCEPT BioRobotics Q3 revenue $35.1M (+72% YoY); raises FY2023 guidance to $133.5M
Revenue $35.1M, up 72% YoY; U.S. handpiece/consumables $17.0M, up 113%.
-
PROCEPT BioRobotics relocates HQ to San Jose, CA
New corporate headquarters at 150 Baytech Drive, San Jose, CA 95134 effective September 12, 2023.
-
PROCEPT BioRobotics closes public offering of 5.1M shares, netting $161.3M
Underwriting agreement with BofA Securities, Piper Sandler, Cowen for 4.42M shares at $33.92/share public price.
-
PROCEPT BioRobotics Q2 revenue $33.1M (+98% YoY); raises FY2023 guidance to $131M
Record 40 U.S. AquaBeam systems sold in Q2; U.S. system revenue $14.8M (+74% YoY).
-
PROCEPT BioRobotics reports annual meeting voting results; all proposals passed
All three director nominees (Moll, Desai, Garrett) elected with 29.3M to 25.2M votes for.
-
PROCEPT BioRobotics reduces required CIBC deposit to $90M, frees excess cash
Loan amendment lowers minimum cash at CIBC to lesser of $90M or all non-operating cash.
-
PROCEPT BioRobotics presents at AUA 2023; no new financial data in filing
Company to present at American Urology Association Annual Meeting on April 28, 2023.
-
PROCEPT BioRobotics Q1 revenue up 72% to $24.4M; raises FY2023 revenue guidance to $128M
Total revenue $24.4M (+72% YoY); U.S. handpiece/consumables $11.8M (+165% YoY).
-
PROCEPT BioRobotics Q4 revenue up 135% YoY to $23.8M; guides 2023 revenue ~$125M
Q4 2022 revenue $23.8M (+135% YoY); full year revenue $75.0M (+118% YoY).
-
PROCEPT BioRobotics pre-announces Q4 rev ~$23.6-23.8M, FY2022 rev ~$74.8-75.0M (+117% YoY)
Q4 2022 revenue expected $23.6M-$23.8M, up from $10.1M in Q4 2021.
-
PROCEPT BioRobotics Q3 revenue $20.3M (+135% YoY), raises 2022 guidance to ~$72.5M
Total revenue $20.3M, +135% YoY; US system rev $9.8M (+95%), handpiece $8.0M (+267%).
-
PROCEPT BioRobotics closes $52M term loan with CIBC, repays $50M Oxford facility
Entered $52M senior secured term loan with CIBC; fully drawn on Oct 6, 2022.
-
PROCEPT BioRobotics Q2 revenue up 97% to $16.7M; raises FY22 revenue guidance to $66-68M
Q2 2022 total revenue $16.7M, +97% YoY; U.S. system revenue $8.5M (+79%), handpiece and consumables $5.7M (+246%).
-
PROCEPT BioRobotics annual meeting elects three directors and ratifies auditor
Thomas Krummel, M.D. elected with 27,027,803 votes for and 1,904,365 withheld; broker non-votes 3,025,300.
-
PROCEPT BioRobotics presents at AUA 2022 Annual Meeting; no material new information disclosed.
Furnished presentation slides for investor meetings at AUA 2022 on May 13, 2022.
-
PROCEPT BioRobotics Q1 revenue $14.2M (+97% YoY); raises FY2022 revenue guidance to $58-62M
Q1 total revenue $14.2M, +97% YoY; U.S. system revenue $7.8M (+70%), handpiece & consumables $4.4M (+174%).
-
PROCEPT BioRobotics Q4 revenue $10.1M (+216% YoY); guides FY2022 revenue $54-58M
Revenue $10.1M in Q4 2021, up from $3.2M YoY; full year $34.5M vs $7.7M.
-
PROCEPT BioRobotics announces preliminary Q4 revenue of $9.8-10.1M, FY 2021 revenue $34.1-34.4M
Q4 2021 revenue expected $9.8M-$10.1M, up from $3.2M in Q4 2020.
-
PROCEPT BioRobotics signs 10-year lease for 158,221 sq ft San Jose facility; appoints Mary Garrett to board
Lease for 158,221 rentable sq ft in San Jose, CA; term 122 months starting on or before Dec 31, 2022.
-
PROCEPT Q3 revenue $8.7M up 314% YoY; raises FY 2021 guide to $33.0-$33.3M
Total revenue of $8.7M vs. $2.1M in Q3 2020; U.S. system revenue $5.0M vs. $0.6M.
-
PROCEPT BioRobotics appoints Elisabeth Sandoval to Board of Directors
Board expanded from eight to nine members; Sandoval appointed as Class I director effective Oct. 21, 2021.
-
PROCEPT BioRobotics adopts amended charter/bylaws upon IPO closing Sep 17, 2021
Authorized common stock increased to 300M shares; 10M shares of undesignated preferred stock authorized.